Bicycle Therapeutics Q2 net loss $39.8M; cash $961.4M after $555M PIPE

BICYCLE THERAPEUTICS PLC

2024-Q2 EPS reported -$1.40 revenue$28,891,000

Net loss of $39.8M ($0.77 loss per share) vs $42.6M ($1.41 loss per share) in Q2 2023; R&D expense $40.1M.
Cash and cash equivalents $961.4M as of June 30, 2024, up from $526.4M at Dec 31, 2023, after $555M PIPE financing.
Pipeline focused on zelenectide pevedotin (BTC) and BT5528; four abstracts accepted for ESMO 2024.
Jennifer Perry promoted to CSO & head of commercial; Nick Keen transitions to advisor; new Clinical Advisory Board formed.
Repaid $31.9M Hercules loan in July 2024 ahead of maturity; financial runway extended into 2H 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.